Cue Biopharma Inc

-0.07 (-2.07%)

Cue Biopharma Receives FDA Acceptance Of IND Application For CUE-102 In WT1

Published: 05/11/2022 12:33 GMT
Cue Biopharma Inc (CUE) - Cue Biopharma Receives FDA Acceptance of Investigational New Drug (ind) Application for Cue-102 in Wilms’ Tumor 1 (wt1) - Expressing Cancers.
Cue Biopharma Inc - to Initiate Phase 1 Dose Escalation and Expansion Trial for Treatment of Wilms' Tumor 1 (wt1) Positive Recurrent/metastatic Cancers.
Cue Biopharma - Starting Dose of 1 Mg/kg Expected to Reduce Time and Cost of Dose Escalation Phase of Trial, Supporting Development Efficiency of Cue-100 Series Platform.